Bayer Ordered to Pay $2 Billion by Georgia Jury in Roundup Cancer Case

Bayer said that it disagrees with the verdict and plans to appeal to get it overturned.
Bayer Ordered to Pay $2 Billion by Georgia Jury in Roundup Cancer Case
Containers of Roundup are displayed on a store shelf in San Francisco on Feb. 24, 2019. Haven Daley/AP Photo
Aldgra Fredly
Updated:
0:00

A Georgia jury on March 21 ordered agrochemical giant Bayer to pay $2.1 billion in damages to a man who claimed he developed cancer after using the company’s Roundup weedkiller, which contains glyphosate.

The jury awarded the plaintiff, John Barnes, $2 billion in punitive damages and $65 million in compensatory damages over claims that Roundup weedkiller caused his non-Hodgkin’s lymphoma, a type of cancer that forms in the lymph system.

Barnes’s lawyer, Kyle Findley, said the ruling was an “important milestone” in the legal battle that began in 2021, adding that the awarded penalties would help the plaintiff get the treatment for his illness.

“It’s been a long road for him ... and he was happy that the truth related to the product [has] been exposed,” Findley said on Sunday.

In a statement, Bayer said that it disagrees with the verdict and plans to appeal to get the decision overturned.

The Germany-based company said the verdict “conflicts with the overwhelming weight of scientific evidence and the consensus of regulatory bodies and their scientific assessments worldwide.”

“We believe that we have strong arguments on appeal to get this verdict overturned and the excessive and unconstitutional damage awards eliminated or reduced,” it stated.

Bayer said that it would “stand fully behind the safety” of Roundup, which it acquired through a $63 billion takeover of U.S. manufacturer Monsanto in 2018.

The company said it remains committed to “trying cases,” noting that it has prevailed in 17 of the past 25 trials. It also noted that some damage awards in previous cases have been reduced by 90 percent from the original jury awards.

“Our track record demonstrates that we win when plaintiffs’ attorneys and their experts are not allowed to misrepresent the worldwide regulatory and scientific assessments that continue to support the products’ safety,” it stated.

The plaintiff accused the company of ignoring several scientific studies related to the toxicity of Roundup and said the company had “tried to find ways to persuade and distract and deny the connection between this product and non-Hodgkin’s lymphoma.”

In 2015, the International Agency for Research on Cancer (IARC)—part of the World Health Organization—classified glyphosate as a probable human carcinogen, a substance that can cause cancer.
The Environmental Protection Agency (EPA) has stated that glyphosate poses “no risks of concern” to human health when used according to its label and considered the ingredient “unlikely to be a human carcinogen.”
The $2.1 billion damages verdict is another court loss for Bayer related to Roundup. In October 2024, a Philadelphia court of common pleas ordered the company to pay $75 million in punitive damages and $3 million in compensatory damages to a plaintiff who claimed to have contracted cancer due to using the weed killer.
The Associated Press contributed to this report.